Exelixis (EXEL) Trading Up 5%

Exelixis, Inc. (NASDAQ:EXEL) was up 5% during mid-day trading on Wednesday . The company traded as high as $28.15 and last traded at $28.02. Approximately 3,543,444 shares traded hands during trading, a decline of 12% from the average daily volume of 4,045,958 shares. The stock had previously closed at $26.68.

A number of equities research analysts have recently issued reports on EXEL shares. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Tuesday, October 10th. SunTrust Banks boosted their price objective on shares of Exelixis from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, October 16th. Needham & Company LLC boosted their price objective on shares of Exelixis from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, October 17th. BidaskClub raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Finally, Oppenheimer reissued a “hold” rating on shares of Exelixis in a research report on Monday, October 16th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $31.38.

The company has a market cap of $8,260.00, a price-to-earnings ratio of 51.12, a price-to-earnings-growth ratio of 1.17 and a beta of 1.89.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.18. The company had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. Exelixis’s quarterly revenue was up 145.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.04) EPS. equities analysts predict that Exelixis, Inc. will post 0.49 EPS for the current fiscal year.

In related news, insider Gisela Schwab sold 100,000 shares of the company’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $23.79, for a total value of $2,379,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Stelios Papadopoulos sold 10,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $25.40, for a total transaction of $254,000.00. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock valued at $3,295,893 in the last ninety days. 5.10% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the stock. Mackenzie Financial Corp boosted its holdings in shares of Exelixis by 24.1% during the 3rd quarter. Mackenzie Financial Corp now owns 10,116 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 1,963 shares during the last quarter. Stifel Financial Corp boosted its holdings in shares of Exelixis by 2.8% during the 3rd quarter. Stifel Financial Corp now owns 72,974 shares of the biotechnology company’s stock valued at $1,768,000 after purchasing an additional 2,009 shares during the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of Exelixis by 17.7% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 14,128 shares of the biotechnology company’s stock valued at $348,000 after purchasing an additional 2,129 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Exelixis by 8.7% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 26,607 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 2,138 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Exelixis by 0.5% during the 3rd quarter. Swiss National Bank now owns 489,200 shares of the biotechnology company’s stock valued at $11,853,000 after purchasing an additional 2,300 shares during the last quarter. 81.15% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/12/21/exelixis-exel-trading-up-5.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply